Detailed Information on Publication Record
2008
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
ZEMANOVÁ, M., Vlastimil ŠČUDLA, Zdeněk ADAM, E. GREGORA, Luděk POUR et. al.Basic information
Original name
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
Name in Czech
Režim nízkodávkovaného thalidomidu u léčby relabovaného nebo refrakterního mnohočetného myelomu
Authors
ZEMANOVÁ, M. (203 Czech Republic), Vlastimil ŠČUDLA (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, guarantor), E. GREGORA (203 Czech Republic), Luděk POUR (203 Czech Republic), J. MINAŘÍK (203 Czech Republic), P. PAVLÍČEK (203 Czech Republic), T. PIKA (203 Czech Republic) and Jaroslav BAČOVSKÝ (203 Czech Republic)
Edition
Neoplasma, Bratislava, Slovak Academic Press, Ltd. 2008, 0028-2685
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.179
RIV identification code
RIV/00216224:14110/08:00035959
Organization unit
Faculty of Medicine
UT WoS
000257128400012
Keywords (in Czech)
mnohočetný myelom; thalidomid
Keywords in English
multiple myeloma; resistance to therapy; thalidomide; cyclophosphamide; dexamethasone
Tags
International impact, Reviewed
Změněno: 24/6/2009 11:15, Mgr. Anna Potáčová, Ph.D.
V originále
Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma. Recently, several studies have shown very good results in therapy combination of thalidomide, cyclophosphamide and dexamethasone, but still high doses of thalidomide associated with serious adverse events have been used. In our study, we performed low-dose thalidomide regimens; the aim of this study was to verify the effect and to assess their toxicity.
In Czech
V této studii jsou popsány režimy léčby v kombinaci s thalidomidem a zhodnocení jejich toxicity.